Floatz logo

Tuvonralimab

Iparomlimab and Tuvonralimab Injection

Tianjin Medical University Cancer Institute and HospitalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Iparomlimab and Tuvonralimab Injection cohort.

Asset / SponsorPhaseRating
Iparomlimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2CCC
(+)-VINCRISTINE
Nanfang Hospital, Southern Medical University
Phase 2CCC
Regorafenib
JIANG LONGWEI
Early Phase 1C

Same molecule, other indications

Tuvonralimab is also rated in:

CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
autoimmune pulmonary disease due to PD-1 deficiencyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →